Omnicell, Inc. (NASDAQ:OMCL) Receives $59.86 Consensus Target Price from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been assigned a consensus rating of “Buy” from the nine ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $59.8571.

Several research firms recently weighed in on OMCL. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a research note on Wednesday, February 4th. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. KeyCorp boosted their target price on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. UBS Group set a $60.00 target price on Omnicell and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Zacks Research upgraded Omnicell from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st.

Key Headlines Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Craig-Hallum raised its price target on Omnicell to $55 from $53 and reiterated a Buy rating after the company’s Q1 update, reinforcing a constructive view on the shares. Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)
• Positive Sentiment: Zacks Research boosted its earnings estimates for multiple periods, including FY2026 to $1.27 per share from $0.87, FY2027 to $1.34 from $1.13, and FY2028 to $1.71 from $1.44, suggesting improving long-term profitability. Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)
• Positive Sentiment: Zacks also increased near-term quarterly EPS forecasts across 2026 and 2027, including Q2 2026 to $0.30 from $0.19 and Q4 2027 to $0.37 from $0.30, while maintaining a Strong-Buy rating, which may support investor confidence. Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)
• Neutral Sentiment: Other analyst notes summarized the broader post-earnings reaction, with multiple firms revising their models after Omnicell’s Q1 2026 beat, adding to the stock’s momentum but not introducing new company-specific catalysts. Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 7,405 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the sale, the executive vice president owned 96,717 shares in the company, valued at approximately $3,355,112.73. The trade was a 7.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC purchased a new stake in Omnicell in the first quarter valued at approximately $16,351,000. Renaissance Technologies LLC lifted its stake in Omnicell by 47.8% in the first quarter. Renaissance Technologies LLC now owns 483,043 shares of the company’s stock valued at $16,124,000 after buying an additional 156,200 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in Omnicell by 6,712.8% in the first quarter. Public Employees Retirement System of Ohio now owns 54,298 shares of the company’s stock valued at $1,812,000 after buying an additional 53,501 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Omnicell by 45.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 279,368 shares of the company’s stock valued at $9,325,000 after buying an additional 87,201 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Omnicell by 21.1% in the first quarter. Sei Investments Co. now owns 148,394 shares of the company’s stock valued at $4,953,000 after buying an additional 25,899 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

OMCL stock opened at $43.12 on Wednesday. The business has a 50 day moving average price of $37.64 and a 200 day moving average price of $40.34. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 98.00, a PEG ratio of 1.13 and a beta of 0.96. Omnicell has a fifty-two week low of $26.84 and a fifty-two week high of $55.00. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.22. The firm had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The firm’s revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Equities research analysts anticipate that Omnicell will post 1.31 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.